Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012; 18(23): 2995-3003 [PMID: 22736924 DOI: 10.3748/wjg.v18.i23.2995]
Corresponding Author of This Article
Yong-Ping Yang, Chief, Center of Therapeutic Research for Liver Cancer, The 302nd Hospital, 100 Xi Si Huan Middle Road, Beijing 100039, China. yongpingyang@hotmail.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 21, 2012; 18(23): 2995-3003 Published online Jun 21, 2012. doi: 10.3748/wjg.v18.i23.2995
Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma
Jian-Hui Qu, Xiu-Juan Chang, Yin-Ying Lu, Wen-Lin Bai, Yan Chen, Lin Zhou, Zhen Zeng, Chun-Ping Wang, Lin-Jing An, Li-Yan Hao, Gui-Lin Xu, Xu-Dong Gao, Min Lou, Ji-Yun Lv, Yong-Ping Yang
Jian-Hui Qu, Xiu-Juan Chang, Yin-Ying Lu, Wen-Lin Bai, Yan Chen, Lin Zhou, Zhen Zeng, Chun-Ping Wang, Lin-Jing An, Li-Yan Hao, Gui-Lin Xu, Xu-Dong Gao, Min Lou, Ji-Yun Lv, Yong-Ping Yang, Center of Therapeutic Research for Liver Cancer, The 302nd Hospital, Beijing 100039, China
Ji-Yun Lv, Yong-Ping Yang, Institute for Infectious Disease, The 302nd Hospital, Beijing 100039, China
Author contributions: Qu JH and Chang XJ contributed equally to this study; Qu JH, Chang XJ, Lv JY and Yang YP designed the research; Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z and Wang CP performed the research; Qu JH, Chang XJ, An LJ, Hao LY, Xu GL, Gao XD and Lou M analyzed the data; Qu JH and Yang YP wrote the paper.
Supported by Grants from the Key Scientific and Technological Research Foundation of the National Special-purpose Program, No. 2008ZX10002-018 and from the Capital Medical Development and Research in Beijing, China, No. 2007-1021 and 2009-2041
Correspondence to: Yong-Ping Yang, Chief, Center of Therapeutic Research for Liver Cancer, The 302nd Hospital, 100 Xi Si Huan Middle Road, Beijing 100039, China. yongpingyang@hotmail.com
Telephone: +86-10-66933429 Fax: +86-10-63879193
Received: August 4, 2011 Revised: March 22, 2012 Accepted: May 6, 2012 Published online: June 21, 2012
Abstract
AIM: To investigate the intratumoral expression of metastasis-associated in colon cancer 1 (MACC1) and c-Met and determine their clinical values associated with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
METHODS: A retrospective study admitted three hundred fifty-four patients with HBV-related HCC. The expression and distribution of MACC1 and c-Met were assessed by quantitative real-time polymerase chain reaction and immunohistochemistry staining. Prognostic factors influencing survival, metastasis and recurrence were assessed.
RESULTS: Intratumoral MACC1 level was found to be associated with HCC disease progression. Both median tumor-free survival (TFS) and overall survival (OS) were significantly shorter in the postoperative HCC patients with high intratumoral MACC1 expression, as compared to those with low intratumoral MACC1 levels (TFS: 34 mo vs 48.0 mo, P < 0.001; OS: 40 mo vs 48 mo, P < 0.01). Multivariable analysis indicated that high MACC1 expression or co-expression with c-Met were independent predictors for HCC clinic outcome (P < 0.001).
CONCLUSION: High intratumoral MACC1 expression can be associated with enhanced tumor progression and poor outcome of HBV-related HCC. MACC1 may serve as a prognostic biomarker for postoperative HCC.
